InvestorsHub Logo

ash111

09/21/18 11:02 AM

#7219 RE: ash111 #7212

$ACAN 3.2 +10% Mentioned it. $AYTU keep holding this lotto for the long term. Used to be a $200m company, w/ FDA approval drugs. Big data later this year ( phase 3). Please check Phase 3 companies Valuation. company is trading 50% below cash on hand and will have more $8m cash when need arrives 
Company products under the spotlight these days:  

Tesla's Elon Musk works 120 hours a week, uses Ambien to sleep  
https://t.co/RzIzNJCZlP ; ;

Drugmakers continue price increases: Aytu BioScience recently bought rights to a spray form of Ambien and then raised the price as much as 843% https://t.co/Dkn6PJQ2SS via @WSJ  ;

" the biggest price increase this month -- of more than 700 percent --came from tiny Aytu BioScience Inc., for an obscure sleep drug called Zolpimist"https://t.co/sSM4gwBgBf ; ;

CEO ...  

“if we only achieved 5% penetration in each of these markets, that would be approximately $90 to $100M net revenue. A rationally-valued specialty pharma comp would be valued at 3 to 5 times net revenue, so that would approximate a $300M to $500”

kei

09/22/18 2:19 PM

#7222 RE: ash111 #7212

thank you ash!!!